Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 50%Moderate 0 · 0%High 4 · 50%

CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower CVD compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.87 [0.8, 0.94]
10 studies · 23868 participants
High

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in all‐cause mortality compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.51 [0.18, 1.4]
5 studies · 1733 participants
Low

Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in myocardial infarction compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 1.45 [0.64, 3.28]
5 studies · 1734 participants
Low

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in any stroke compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.85 [0.13, 5.61]
5 studies · 1734 participants
Low

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower all‐cause mortality compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.83 [0.72, 0.96]
12 studies · 24797 participants
High

Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower myocardial infarction compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.86 [0.79, 0.94]
9 studies · 23352 participants
High

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower any stroke compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.73 [0.58, 0.91]
8 studies · 22835 participants
High

CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in CVD compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 1.37 [0.65, 2.87]
3 studies · 1379 participants
Low